Navigation Links
Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
Date:12/11/2008

static breast cancer. Women in the study were randomized to compare the efficacy of first-line therapy with lapatinib, a small-molecule tyrosine kinase inhibitor, and the aromatase inhibitor letrozole versus letrozole monotherapy. At randomization patients received either letrozole 2.5 mg once daily (QD) plus lapatinib 1500 mg QD, or letrozole 2.5 mg QD plus placebo. The primary endpoint of EGF30008 was PFS in the HR+/HER2+/ErbB2+ population, and secondarily in the overall ITT population. Secondary endpoints included overall response rate (ORR), clinical benefit rate (CBR), time to response, duration of response, overall survival, safety assessments and quality of life. Hormonal therapy was allowed in the adjuvant setting only (1 year prior to study entry) and crossover was not permitted.

About TYKERB(R) (lapatinib)

Lapatinib is an oral small-molecule inhibitor of the HER2/ErbB2 tyrosine kinase receptor. Stimulation of HER2/ErbB2 is associated with cell proliferation and with multiple processes involved in tumor progression and metastases. Overexpression of these receptors has been reported in a variety of human tumors and is associated with poor prognosis and reduced overall survival.

Lapatinib is approved in 63 countries. On March 13, 2007, the United States Food and Drug Administration (FDA) approved lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2/ErbB2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. On June 10, 2008, the European Commission adopted a decision to grant a conditional marketing authorization for lapatinib in all 27 European Union (EU) member states. Other countries include Australia, India, Brazil, Russia, Turkey, South Korea, Taiwan and others around the world. Registration dossiers for lapatinib have been filed in Canada, China, Japan, Mexic
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... VA (PRWEB) July 23, 2014 Inventor ... America: From football games to the gas pump – ... guests on Wednesday, July 30 at Noon. , With ... Legislator has more patents than anyone in the General ... football’s superimposed yellow line yard marker as seen on ...
(Date:7/23/2014)... The National Institute of Biomedical Imaging and Bioengineering ... Symposium on July 30, 2014 on the NIH campus. ... investigators covering a wide breadth of NIBIB-funded research. ... Cohen, Harvard, Engineering Microbial Rhodopsins as Optical Voltage Sensor, ... Fluorescently Labeled Probes for Nerve Imaging ...
(Date:7/23/2014)... Bodybuilding.com, the Internet’s most-visited bodybuilding and fitness ... has officially opened the polls for their tenth annual ... growing sports nutrition company, is up for eight awards ... Best Tasting Protein of the Year- Whey-HD™, Most Innovative ... - Whey-HD™, Pre-workout Supplement of the Year - 1.M.R ...
(Date:7/23/2014)... 23, 2014 Olympic gold medal-winning speed ... Virginia on Friday, July 18. Hedrick visited Roanoke as ... Commonwealth Games, an Olympic-style event celebrating its 25th Anniversary ... as a premier sponsor of the Commonwealth Games, which ... all ages and all activity levels. , Hedrick, a ...
(Date:7/23/2014)... effort to catalog the molecular causes of stomach ... have identified four subtypes of tumors based on ... the new classification promises to advance clinical research ... killer worldwide. , In a report in ... Research Network said they analyzed 295 samples of ...
Breaking Medicine News(10 mins):Health News:Celebrating Innovation and Invention 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3
... had a piercing somewhere other than their ear lobe, with ... in a hospital admission, according to a study published on ... public health doctors from the Health Protection Agency and the ... women are three times more likely than men to have ...
... Key, WASHINGTON, June 13 A team ... to Germany on Saturday,to work with the US ... current rehabilitation practices. They will also make,recommendations for ... to,injured soldiers and other military personnel in need ...
... findings suggest men fighting over women took place even in ... fighting over women? Nothing new there, based on the findings ... Durham University-led researchers say that genetic evidence from 34 skeletons ... the result of a tribal war over the need for ...
... The Blinded,American Veterans Foundation (BAVF), at its June ... Delegate Sheila Hixson., "We,re honored to recognize Delegate ... District 20 and to the entire State of,Maryland," said ... efforts as a legislator and community activist are known,throughout ...
... Leading Cause of Work Disability in Europe, ... that treating patients with early, active rheumatoid arthritis ... in an,indirect cost savings of euro 4,845 (or ... the study) per patient per year compared to,MTX ...
... Effort to Find Cure, WASHINGTON, June 12 ... died in 2005 of peritoneal,mesothelioma, will be a ... June 27th, part of the Mesothelioma Applied Research ... 26th through Saturday, June 28th at the Hyatt ...
Cached Medicine News:Health News:1 in 10 adults has a non-earlobe piercing 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:Pursuit of Females Dates Way, Way Back 2Health News:Blinded Vets Foundation to Honor Maryland State Delegate Sheila Hixson 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 4Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 5Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 6Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 7Health News:Asbestos Tragedy and Hope 2
(Date:7/23/2014)... -- The Board of Directors of VirtualScopics, Inc. (NASDAQ: ... trial imaging solutions, announced today that Eric T. ... executive officer, effective immediately.  Mr. Converse joined the company,s ... the positions of interim president and chief executive officer ... E. Phelps , Ph.D., chairman of the company,s Board ...
(Date:7/23/2014)... Wis. and MOUNTAIN VIEW, Calif. ... ("Surpass"), a recognized leader in translational preclinical research, today ... www.surpassinc.com ), signaling the transformation of Surpass, corporate ... innovation partner for our customers. This press release comes ... two integral hires were added to the Silicon Valley ...
(Date:7/23/2014)... 23, 2014 Pharmavite LLC announced that Timothy ... officer effective immediately. Toll recently served as Pharmavite,s executive ... category management, private label and sales administration in ... global role, Toll will expand his responsibilities to include ... "Toll,s appointment to chief customer officer is part ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... to Millennium Research Group (MRG), the global authority on medical ... to be used in a narrow set of indications over ... at a much lower rate than previously expected.  With a ... to the nonfusion market as a whole which is growing ...
... CAMBRIDGE, Mass., Sept. 1 Pfizer Inc. ... Pharmaceuticals, Inc., a privately held drug discovery ... they have entered into an agreement under ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years 2European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years 3Pfizer to Acquire FoldRx Pharmaceuticals 2Pfizer to Acquire FoldRx Pharmaceuticals 3Pfizer to Acquire FoldRx Pharmaceuticals 4Pfizer to Acquire FoldRx Pharmaceuticals 5Pfizer to Acquire FoldRx Pharmaceuticals 6
Button shape tip, round serrated handle, dull finish, overall length 130 mm....
... is the first and only one-bottle lens ... and conditions gas permeable contact lenses, but ... to the leading two-bottle GP lens care ... upon insertion by enveloping the lenses and ...
Overall length 355 mm, 14.0 inches....
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
Medicine Products: